Influence of glucose transporter 1 activity inhibition on neuroblastoma in vitro

Peng, Yan; Xing, Sining; Tang, Hu-Ying; Wang, Chang-dong; Yi, Faping; Liu, Geli; Wu, Xiangbing

doi:10.1016/j.gene.2018.12.010

Cited by 25 publications

(15 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These molecules are overexpressed in cancer cells; therefore, their inhibition can be a therapeutic strategy against cancer (20,21). The use of compounds that suppress the growth of cancer cells through inhibition of glucose transporters has been widely explored in various types of cancer, including liver, colon, ovary, prostate, brain, and breast cancer (21)(22)(23)(24)(25)(26). For example, in ovarian cancer cells, GLUT-1 and GLUT-3 protein levels are increased 6.5 and 4.1 times, respectively, and a GLUT-1/-3 inhibitor prevents cell growth, targets metabolic plasticity, and overcomes the cellular rescue mechanisms of cancer cells (22).…”

Section: Glucose Metabolism and Transporters In Cancer Cellsmentioning

confidence: 99%

Glycosylated Nanoparticles for Cancer-Targeted Drug Delivery

Torres-Pérez

Pedraza-Escalona

et al. 2020

Front. Oncol.

View full text Add to dashboard Cite

Nanoparticles (NPs) are novel platforms that can carry both cancer-targeting molecules and drugs to avoid severe side effects due to nonspecific drug delivery in standard chemotherapy treatments. Cancer cells are characterized by abnormal membranes, metabolic changes, the presence of lectin receptors, glucose transporters (GLUT) overexpression, and glycosylation of immune receptors of programmed death on cell surfaces. These characteristics have led to the development of several strategies for cancer therapy, including a large number of carbohydrate-modified NPs, which have become desirable for use in cell-selective drug delivery systems because they increase nanoparticle-cell interactions and uptake of carried drugs. Currently, the potential of NP glycosylation to enhance the safety and efficacy of carried therapeutic antitumor agents has been widely acknowledged, and much information is accumulating in this field. This review seeks to highlight recent advances in NP stabilization, toxicity reduction, and pharmacokinetic improvement and the promising potential of NP glycosylation from the perspective of molecular mechanisms described for drug delivery systems for cancer therapy. From preclinical proof-of-concept to demonstration of therapeutic value in the clinic, the challenges and opportunities presented by glycosylated NPs, with a focus on their applicability in the development of nanodrugs, are discussed in this review.

show abstract

Section: Glucose Metabolism and Transporters In Cancer Cellsmentioning

confidence: 99%

Glycosylated Nanoparticles for Cancer-Targeted Drug Delivery

Torres-Pérez

Pedraza-Escalona

et al. 2020

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…It was hypothesized that one possible explanation for this could lie in the fact that little more than half of human malignomas express one of the major glucose transporters GLUT1 [ 20 ]. Peng et al showed that inhibition of GLUT1 in neuroblastoma cells led to a decrease in cell proliferation, inducing cell cycle arrest [ 21 ]. It has been suggested that inhibition of GLUT1 could present a target for tumor therapy [ 21 , 22 ].…”

Section: Discussionmentioning

confidence: 99%

“…Peng et al showed that inhibition of GLUT1 in neuroblastoma cells led to a decrease in cell proliferation, inducing cell cycle arrest [ 21 ]. It has been suggested that inhibition of GLUT1 could present a target for tumor therapy [ 21 , 22 ]. Furthermore, the inactivation of GLUT1 leads to a reduced proliferation, invasion and migration of the neuroblastoma cells [ 21 ].…”

Section: Discussionmentioning

confidence: 99%

Increased Proliferation of Neuroblastoma Cells under Fructose Metabolism Can Be Measured by Isothermal Microcalorimetry

et al. 2021

View full text Add to dashboard Cite

Neuroblastoma, like other cancer types, has an increased need for energy. This results in an increased thermogenic profile of the cells. How tumor cells optimize their energy efficiency has been discussed since Warburg described the fact that tumor cells prefer an anaerobic to an aerobic metabolism in the 1920s. An important question is how far the energy efficiency is influenced by the substrate. The aim of this study was to investigate how the metabolic activity of neuroblastoma cells is stimulated by addition of glucose or fructose to the medium and if this can be measured accurately by using isothermal microcalorimetry. Proliferation of Kelly and SH-EP Tet-21/N cells was determined in normal medium, in fructose-enriched, in glucose-enriched and in a fructose/glucose-enriched environment. Heat development of cells was measured by isothermal microcalorimetry. The addition of fructose, glucose or both to the medium led to increases in the metabolic activity of the cells, resulting in increased proliferation under the influence of fructose. These changes were reflected in an enhanced thermogenic profile, mirroring the results of the proliferation assay. The tested neuroblastoma cells prefer fructose metabolism over glucose metabolism, a quality that provides them with a survival benefit under unfavorable low oxygen and low nutrient supply when fructose is available. This can be quantified by measuring thermogenesis.

show abstract

“…Its usefulness as a radiosensitizer needs to be investigated. WZB117, another promising GLUT1 inhibitor, re-sensitizes therapy-resistant breast cancer cells to radiotherapy and demonstrates anti-cancer effects in glioblastoma cells ( 36 , 37 ).…”

Section: Improving Radiotherapy Response By Tumor Sensitizationmentioning

confidence: 99%

Metabolic Rewiring in Radiation Oncology Toward Improving the Therapeutic Ratio

2021

View full text Add to dashboard Cite

To meet the anabolic demands of the proliferative potential of tumor cells, malignant cells tend to rewire their metabolic pathways. Although different types of malignant cells share this phenomenon, there is a large intracellular variability how these metabolic patterns are altered. Fortunately, differences in metabolic patterns between normal tissue and malignant cells can be exploited to increase the therapeutic ratio. Modulation of cellular metabolism to improve treatment outcome is an emerging field proposing a variety of promising strategies in primary tumor and metastatic lesion treatment. These strategies, capable of either sensitizing or protecting tissues, target either tumor or normal tissue and are often focused on modulating of tissue oxygenation, hypoxia-inducible factor (HIF) stabilization, glucose metabolism, mitochondrial function and the redox balance. Several compounds or therapies are still in under (pre-)clinical development, while others are already used in clinical practice. Here, we describe different strategies from bench to bedside to optimize the therapeutic ratio through modulation of the cellular metabolism. This review gives an overview of the current state on development and the mechanism of action of modulators affecting cellular metabolism with the aim to improve the radiotherapy response on tumors or to protect the normal tissue and therefore contribute to an improved therapeutic ratio.

show abstract

Influence of glucose transporter 1 activity inhibition on neuroblastoma in vitro

Cited by 25 publications

References 31 publications

Glycosylated Nanoparticles for Cancer-Targeted Drug Delivery

Glycosylated Nanoparticles for Cancer-Targeted Drug Delivery

Increased Proliferation of Neuroblastoma Cells under Fructose Metabolism Can Be Measured by Isothermal Microcalorimetry

Metabolic Rewiring in Radiation Oncology Toward Improving the Therapeutic Ratio

Contact Info

Product

Resources

About